Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/NFKBIA_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/NFKBIA_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/NFKBIA_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/NFKBIA_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/NFKBIA_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/NFKBIA_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/NFKBIA_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/NFKBIA_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/NFKBIA_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/NFKBIA_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/NFKBIA_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/NFKBIA_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/NFKBIA_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00511019 | Breast | Precancer | regulation of DNA binding | 22/1080 | 118/18723 | 9.28e-07 | 3.71e-05 | 22 |
GO:00451859 | Breast | Precancer | maintenance of protein location | 19/1080 | 94/18723 | 1.43e-06 | 5.35e-05 | 19 |
GO:00510989 | Breast | Precancer | regulation of binding | 44/1080 | 363/18723 | 2.59e-06 | 8.65e-05 | 44 |
GO:00092667 | Breast | Precancer | response to temperature stimulus | 27/1080 | 178/18723 | 3.85e-06 | 1.21e-04 | 27 |
GO:00300999 | Breast | Precancer | myeloid cell differentiation | 45/1080 | 381/18723 | 4.00e-06 | 1.25e-04 | 45 |
GO:00512358 | Breast | Precancer | maintenance of location | 40/1080 | 327/18723 | 5.85e-06 | 1.71e-04 | 40 |
GO:00022378 | Breast | Precancer | response to molecule of bacterial origin | 43/1080 | 363/18723 | 6.05e-06 | 1.72e-04 | 43 |
GO:00507293 | Breast | Precancer | positive regulation of inflammatory response | 23/1080 | 142/18723 | 6.51e-06 | 1.81e-04 | 23 |
GO:00324968 | Breast | Precancer | response to lipopolysaccharide | 41/1080 | 343/18723 | 7.94e-06 | 2.17e-04 | 41 |
GO:0050727 | Breast | Precancer | regulation of inflammatory response | 44/1080 | 386/18723 | 1.26e-05 | 3.22e-04 | 44 |
GO:00456379 | Breast | Precancer | regulation of myeloid cell differentiation | 28/1080 | 210/18723 | 3.05e-05 | 6.72e-04 | 28 |
GO:00321034 | Breast | Precancer | positive regulation of response to external stimulus | 46/1080 | 427/18723 | 3.41e-05 | 7.40e-04 | 46 |
GO:19037069 | Breast | Precancer | regulation of hemopoiesis | 41/1080 | 367/18723 | 3.95e-05 | 8.52e-04 | 41 |
GO:00313493 | Breast | Precancer | positive regulation of defense response | 33/1080 | 278/18723 | 6.79e-05 | 1.36e-03 | 33 |
GO:00713568 | Breast | Precancer | cellular response to tumor necrosis factor | 28/1080 | 229/18723 | 1.42e-04 | 2.45e-03 | 28 |
GO:00346128 | Breast | Precancer | response to tumor necrosis factor | 29/1080 | 253/18723 | 3.32e-04 | 4.70e-03 | 29 |
GO:00712227 | Breast | Precancer | cellular response to lipopolysaccharide | 25/1080 | 209/18723 | 4.41e-04 | 5.85e-03 | 25 |
GO:00712167 | Breast | Precancer | cellular response to biotic stimulus | 28/1080 | 246/18723 | 4.67e-04 | 6.14e-03 | 28 |
GO:00725948 | Breast | Precancer | establishment of protein localization to organelle | 41/1080 | 422/18723 | 7.75e-04 | 9.20e-03 | 41 |
GO:00712197 | Breast | Precancer | cellular response to molecule of bacterial origin | 25/1080 | 221/18723 | 1.00e-03 | 1.12e-02 | 25 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05208113 | Prostate | BPH | Chemical carcinogenesis - reactive oxygen species | 114/1718 | 223/8465 | 3.05e-25 | 1.44e-23 | 8.91e-24 | 114 |
hsa05171113 | Prostate | BPH | Coronavirus disease - COVID-19 | 115/1718 | 232/8465 | 5.65e-24 | 2.07e-22 | 1.28e-22 | 115 |
hsa05132113 | Prostate | BPH | Salmonella infection | 99/1718 | 249/8465 | 7.26e-13 | 1.50e-11 | 9.27e-12 | 99 |
hsa05131112 | Prostate | BPH | Shigellosis | 94/1718 | 247/8465 | 5.19e-11 | 9.51e-10 | 5.89e-10 | 94 |
hsa0521514 | Prostate | BPH | Prostate cancer | 48/1718 | 97/8465 | 1.08e-10 | 1.87e-09 | 1.16e-09 | 48 |
hsa05130113 | Prostate | BPH | Pathogenic Escherichia coli infection | 77/1718 | 197/8465 | 7.09e-10 | 1.11e-08 | 6.89e-09 | 77 |
hsa05166112 | Prostate | BPH | Human T-cell leukemia virus 1 infection | 79/1718 | 222/8465 | 6.00e-08 | 6.83e-07 | 4.23e-07 | 79 |
hsa05167112 | Prostate | BPH | Kaposi sarcoma-associated herpesvirus infection | 69/1718 | 194/8465 | 4.22e-07 | 4.10e-06 | 2.54e-06 | 69 |
hsa05169112 | Prostate | BPH | Epstein-Barr virus infection | 70/1718 | 202/8465 | 1.06e-06 | 9.74e-06 | 6.03e-06 | 70 |
hsa0522214 | Prostate | BPH | Small cell lung cancer | 38/1718 | 92/8465 | 3.15e-06 | 2.74e-05 | 1.69e-05 | 38 |
hsa0520313 | Prostate | BPH | Viral carcinogenesis | 69/1718 | 204/8465 | 3.40e-06 | 2.87e-05 | 1.78e-05 | 69 |
hsa05163111 | Prostate | BPH | Human cytomegalovirus infection | 74/1718 | 225/8465 | 4.87e-06 | 3.92e-05 | 2.43e-05 | 74 |
hsa0513519 | Prostate | BPH | Yersinia infection | 49/1718 | 137/8465 | 1.65e-05 | 1.27e-04 | 7.86e-05 | 49 |
hsa0512016 | Prostate | BPH | Epithelial cell signaling in Helicobacter pylori infection | 29/1718 | 70/8465 | 4.25e-05 | 2.98e-04 | 1.85e-04 | 29 |
hsa0466815 | Prostate | BPH | TNF signaling pathway | 41/1718 | 114/8465 | 6.86e-05 | 4.35e-04 | 2.69e-04 | 41 |
hsa0522017 | Prostate | BPH | Chronic myeloid leukemia | 30/1718 | 76/8465 | 9.26e-05 | 5.77e-04 | 3.57e-04 | 30 |
hsa0514519 | Prostate | BPH | Toxoplasmosis | 40/1718 | 112/8465 | 1.00e-04 | 6.00e-04 | 3.71e-04 | 40 |
hsa0421017 | Prostate | BPH | Apoptosis | 46/1718 | 136/8465 | 1.41e-04 | 8.31e-04 | 5.14e-04 | 46 |
hsa05417112 | Prostate | BPH | Lipid and atherosclerosis | 66/1718 | 215/8465 | 1.68e-04 | 9.56e-04 | 5.92e-04 | 66 |
hsa0516112 | Prostate | BPH | Hepatitis B | 52/1718 | 162/8465 | 2.42e-04 | 1.27e-03 | 7.85e-04 | 52 |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4792 | NFKBIA | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR BINDING, DRUGGABLE GENOME | | 6-METHOXYCOMAPARVIN | CHEMBL401565 | 18088098 |
4792 | NFKBIA | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR BINDING, DRUGGABLE GENOME | | 6-METHOXYCOMAPARVIN 5-METHYL ETHER | CHEMBL256967 | 18088098 |
4792 | NFKBIA | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR BINDING, DRUGGABLE GENOME | | DEMETHYLWEDELOLACTONE | DEMETHYLWEDELOLACTONE | 22926226 |
4792 | NFKBIA | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR BINDING, DRUGGABLE GENOME | | GAMBOGIC ACID | GAMBOGIC ACID | 22472167 |
4792 | NFKBIA | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR BINDING, DRUGGABLE GENOME | | gefitinib | GEFITINIB | 31664190 |
4792 | NFKBIA | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR BINDING, DRUGGABLE GENOME | | (+)-TUBERIFERIN | CHEMBL1940084 | 22153345 |
4792 | NFKBIA | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR BINDING, DRUGGABLE GENOME | | WEDELOLACTONE | WEDELOLACTONE | 22926226 |
4792 | NFKBIA | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR BINDING, DRUGGABLE GENOME | | DIOSCIN | DIOSCIN | 23621869 |
4792 | NFKBIA | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR BINDING, DRUGGABLE GENOME | | PEPEROMIN E | PEPEROMIN E | 19559609 |